https://www.selleckchem.com/products/sq22536.html
5 years) received omalizumab for cancer therapy-related paCAEs (71% CPIs; 29% anti-HER2). All had solid tumors (29% breast, 29% genitourinary, 15% lung, 26% other), and most (n= 18, 64%) presented with an urticarial phenotype. In total 28 of 34 (82%) patients responded to omalizumab. The proportion of patients receiving oral corticosteroids as supportive treatment for management of paCAEs decreased with IgE blockade, from 50% to 9% (P 0.001). Ten of 32 (31%) patients had interruption of oncologic therapy due to skin toxicity; four
Gusto
Magkomento
Ibahagi
